Capricor Therapeutics Inc (CAPR, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Capricor Therapeutics Inc is a clinical stage biotechnology company developing products for the treatment of cardiovascular diseases with a focus on heart failure. Capricor Therapeutics Inc has a market cap of $37.190 million; its shares were traded at around $1.42 with and P/S ratio of 10.08. Capricor Therapeutics Inc had annual average EBITDA growth of 34.80% over the past ten years.
For the last quarter Capricor Therapeutics Inc reported a revenue of $0.48 million, compared with the revenue of $0.91 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $2.67 million, a decrease of 33.3% from the previous year. For the last five years Capricor Therapeutics Inc had an average revenue growth rate of 25.9% a year.
The reported diluted earnings per share was 9 cents for the year, compared with the loss per share of $0.85 in the previous year. The Capricor Therapeutics Inc had an operating margin of -482.45%, compared with the operating margin of -424.53% a year before. The 10-year historical median operating margin of Capricor Therapeutics Inc is -361.55%. The profitability rank of the company is 2 (out of 10).
At the end of the fiscal year, Capricor Therapeutics Inc has the cash and cash equivalents of $14.1 million, compared with $3.20 million in the previous year. The company had no long term debt, compared with $13.9 million in the previous year. Capricor Therapeutics Inc has a financial strength rank of 4 (out of 10).
At the current stock price of $1.42, Capricor Therapeutics Inc is traded at 38.8% discount to its historical median P/S valuation band of $2.32. The P/S ratio of the stock is 10.08, while the historical median P/S ratio is 16.48. The stock lost 49.19% during the past 12 months.
For the complete 20-year historical financial data of CAPR, click here.
